ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 317 filers reported holding ROYALTY PHARMA PLC in Q2 2023. The put-call ratio across all filers is 0.31 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,917,305 | +15.5% | 70,645 | +30.9% | 0.00% | 0.0% |
| Q2 2023 | $1,659,591 | +13.1% | 53,988 | +32.6% | 0.00% | 0.0% |
| Q1 2023 | $1,467,142 | -11.2% | 40,720 | -2.6% | 0.00% | 0.0% |
| Q4 2022 | $1,652,133 | +57.5% | 41,805 | +60.2% | 0.00% | 0.0% |
| Q3 2022 | $1,049,000 | -81.4% | 26,103 | -80.5% | 0.00% | -66.7% |
| Q2 2022 | $5,635,000 | +10.8% | 134,049 | +2.7% | 0.00% | +50.0% |
| Q1 2022 | $5,086,000 | -1.6% | 130,571 | +0.6% | 0.00% | 0.0% |
| Q4 2021 | $5,171,000 | +1034.0% | 129,780 | +929.2% | 0.00% | – |
| Q3 2021 | $456,000 | -97.3% | 12,610 | -97.0% | 0.00% | -100.0% |
| Q2 2021 | $16,993,000 | -65.2% | 414,553 | -63.0% | 0.01% | -70.0% |
| Q1 2021 | $48,877,000 | -12.7% | 1,120,505 | +0.2% | 0.02% | -16.7% |
| Q4 2020 | $55,966,000 | +11.7% | 1,118,204 | -6.1% | 0.02% | 0.0% |
| Q3 2020 | $50,123,000 | -3.0% | 1,191,422 | -0.7% | 0.02% | -11.1% |
| Q2 2020 | $51,684,000 | – | 1,200,000 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | 2,680,644 | $106,824,000 | 67.12% |
| SIGULER GUFF ADVISERS, LLC | 6,761,970 | $269,465,000 | 56.37% |
| Vantage Consulting Group Inc | 4,601,152 | $183,355,000 | 49.30% |
| Indie Asset Partners, LLC | 805,982 | $32,118,000 | 23.31% |
| HARVARD MANAGEMENT CO INC | 3,464,990 | $138,080,000 | 12.96% |
| Brown University | 621,759 | $24,777,000 | 6.04% |
| Overbrook Management Corp | 729,125 | $29,056,000 | 5.86% |
| Bleichroeder LP | 824,033 | $32,838,000 | 5.13% |
| Geo Capital Gestora de Recursos Ltd | 200,692 | $7,998,000 | 3.81% |
| Lagoda Investment Management, L.P. | 140,435 | $5,596,000 | 2.65% |